



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C12N 15/00, 1/21, 15/11 A61K 39/00	A1	(11) International Publication Number: WO 92/01783 (43) International Publication Date: 6 February 1992 (06.02.92)
(21) International Application Number: PCT/US91/04833 (22) International Filing Date: 9 July 1991 (09.07.91) (30) Priority data: 553,907 16 July 1990 (16.07.90) US (71) Applicants: ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY [US/US]; 1300 Morris Park Avenue, Bronx, NY 10461 (US). UNIVERSITY OF PITTSBURGH [US/US]; 911 William Pitt Union, Pittsburgh, PA 15260 (US). (72) Inventors: JACOBS, William, R. ; 163 Fordham Street, City Island, NY 10464 (US). HATFULL, Graham ; 5 Forbes Terrace, Pittsburgh, PA 15217 (US).		(74) Agents: OLSTEIN, Elliot, M. et al.; Carella, Byrne, Bain, Gilfillan, Cecchi & Stewart, 6 Becker Farm Road, Roseland, NJ 07068 (US). (81) Designated States: AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent). Published <i>With international search report.</i>
(54) Title: DNA CAPABLE OF SITE-SPECIFIC INTEGRATION INTO MYCOBACTERIA (57) Abstract A DNA for integrating DNA into a mycobacterium chromosome portion which includes a first DNA sequence which is a phage DNA portion encoding bacteriophage integration into a mycobacterium chromosome, and a second DNA sequence encoding a protein or polypeptide heterologous to the mycobacterium in which the DNA is to be integrated. Such DNA may be integrated into mycobacteria, which may then be administered as a vaccine and/or therapeutic agent.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

-1-

**DNA CAPABLE OF SITE-SPECIFIC INTEGRATION
INTO MYCOBACTERIA**

This invention relates to DNA capable of integrating into mycobacterial chromosomes. More particularly, this invention relates to DNA which is capable of site-specific integration into a mycobacterium chromosome while containing a DNA sequence encoding a protein heterologous to the mycobacterium in which the DNA is integrated.

Certain mycobacteria represent major pathogens of man and animals. For example, tuberculosis is generally caused in humans by Mycobacterium tuberculosis, and in cattle by Mycobacterium bovis, which may also be transmitted to humans and other animals. Mycobacteria leprae is the causative agent of leprosy. M. tuberculosis and mycobacteria of the avium-intracellulare-scrofulaceum group (MAIS group) represent major opportunistic pathogens of patients with acquired immune deficiency syndrome (AIDS). M. pseudotuberculosis is a major pathogen of cattle.

On the other hand, Bacille Calmette-Guerin, or BCG, an avirulent strain of M. bovis, is widely used in human vaccines, and in particular is used as a live vaccine, which is protective against tuberculosis. BCG is the only childhood vaccine which is currently given at birth, has a very low incidence of adverse effects, and can be used repeatedly in an individual (eg., in multiple forms). In addition, BCG and other mycobacteria (eg.,

M. smegmatis), employed in vaccines, have adjuvant properties among the best currently known and, therefore, stimulate a recipient's immune system to respond to antigens with great effectiveness.

It has been suggested by Jacobs, et al, Nature, Vol. 327, No. 6122, pgs. 532-535 (June 11, 1987) that BCG could be used as a host for the construction of recombinant vaccines. In other words, it was suggested to take an existing vaccine (in this case against tuberculosis) and expand its protective repertoire through the introduction of one or more genes from other pathogens. Because BCG vaccines are administered as live bacteria, it is essential that any foreign antigens, polypeptides, or proteins expressed by the bacteria are not lost from the bacteria subsequent to vaccination.

Transformation, the process whereby naked DNA is introduced into bacterial cells, has been carried out successfully in mycobacteria. Jacobs, et al (1987), hereinabove cited, have described transformation of mycobacteria through chemical methods, and Snapper, et al. PNAS, Vol. 85, pgs. 6987-6991 (September 1988) have described transformation of mycobacteria by electroporation. Electroporation can give from 10^5 to 10^6 transformants per μg of plasmid DNA and such plasmid DNA's may carry genes for resistance to antibiotic markers such as kanamycin (Snapper, et al 1988) to allow for selection of transformed cells from non-transformed cells.

Jacobs, et al (1987) and Snapper, et al (1988) have also described the use of cloning vehicles, such as plasmids and bacteriophages, for carrying genes of interest into mycobacteria.

Combination of the above-mentioned techniques, along with standard tools of molecular cloning (e.g., use of restriction enzymes, etc.) allows the cloning of genes of interest into vectors and introduction of such genes into mycobacteria. To express these genes, it is important to have available signals for gene expression, in particular, transcription promoter

elements. Such promoter elements have been isolated from mycobacterial heat shock genes, and used to express foreign antigens in mycobacteria.

Plasmids currently available for use in mycobacteria, however, are not stably maintained, and are readily lost during non-selective growth. If recombinant mycobacteria expressing genes of interest are to be employed as vaccines against a particular antigen or as a means of providing a therapeutic agent to a host, which is expressed by the mycobacteria, it is crucial that such genes not be lost from the recombinant mycobacteria subsequent to their administration.

It is an object of the present invention to introduce into mycobacteria and ultimately express a variety of heterologous genes, including, but not limited to, genes for protective antigen(s) for a variety of pathogens, and/or for other therapeutic agents, thereby enabling one to produce effective vaccines against such pathogens and/or to provide effective therapeutic agents, whereby such genes will not be lost subsequent to vaccination or administration of the therapeutic agent.

In accordance with an aspect of the present invention, there is provided a DNA which comprises a first DNA sequence which is a phage DNA portion encoding bacteriophage integration into a mycobacterium chromosome, and a second DNA sequence encoding at least one protein or polypeptide which is heterologous to the mycobacterium in which the DNA is to be integrated.

The term "phage DNA portion", as used herein, means that the DNA sequence is derived from a phage and lacks the DNA which is required for phage replication.

Bacteriophages from which the phage DNA portion may be derived include, but are not limited to, mycobacteriophages, such as but not limited to the L5, L1, Bxb1 and TM4 mycobacteriophages; the lambda phage of E.coli; the toxin phages

of Corynebacteria; phages of Actinomycetes and Norcadia, the ϕ C31 phage of Streptomyces; and the P22 phage of Salmonella. Preferably, the phage DNA portion encodes mycobacteriophage integration into a mycobacterium chromosome.

In a preferred embodiment, the first DNA sequence includes DNA encoding integrase, which is a protein that provides for integration of the DNA into the mycobacterial chromosome. Most preferably, the first DNA sequence also includes DNA which encodes an AttP site.

The DNA sequence encoding the AttP site and the integrase provides for an integration event which is referred to as site-specific integration. DNA containing the AttP site and the integrase gene is capable of integration into a corresponding AttB site of a mycobacterium chromosome.

It is to be understood that the exact DNA sequence encoding the attP site may vary among different phages, and that the exact DNA sequence encoding the attB site may vary among different mycobacteria.

The integration event results in the formation of two new junction sites called AttL and AttR, each of which contain part of each of AttP and AttB. The inserted and integrated non-phage DNA which includes the first and second DNA sequences, is flanked by the AttL and AttR sites. The insertion and integration of the phage DNA portion results in the formation of a transformed mycobacterium.

Applicants have found that, when employing the phage DNA portion of the present invention for integration into mycobacterial chromosome, the gene(s) of interest which is integrated into the mycobacterial chromosome is not lost following non-selective growth of the mycobacteria. Thus, the gene(s) of interest may be expressed by the mycobacteria following such non-selective growth, thus making such transformed mycobacteria excellent vehicles to be employed in vaccines or pharmaceuticals whereby such mycobacteria will express antigens

and/or therapeutic agents of interest subsequent to administration of the recombinant mycobacteria to a host.

Mycobacteria into which the phage DNA portion may be integrated include, but are not limited to, Mycobacterium bovis-BCG, M. smegmatis, M. avium, M. phlei, M. fortuitum, M. lufu, M. paratuberculosis, M. habana, M. scrofalaceum, M. leprae and M. intracellulare. In a preferred embodiment, the DNA is integrated into Mycobacterium bovis- BCG.

The second DNA sequence which encodes a protein heterologous to mycobacteria may be DNA which is all or a portion of a gene encoding protein(s) or polypeptide(s) of interest; DNA encoding a selectable marker or markers; or DNA encoding both a selectable marker or markers and at least one protein or polypeptide of interest.

Proteins or polypeptides of interest, which may be encoded by the second DNA sequence include, but are not limited to, antigens, anti-tumor agents, enzymes, lymphokines, pharmacologic agents, immunopotentiators, and reporter molecules of interest in a diagnostic context.

Antigens for which the second DNA sequence may encode include, but are not limited to, Mycobacterium leprae antigens; Mycobacterium tuberculosis antigens; Rickettsia antigens; malaria sporozoites and merozoites; diphtheria toxoids; tetanus toxoids; Clostridium antigens; Leishmania antigens; Salmonella antigens; Borrelia antigens; Mycobacterium africanum antigens; Mycobacterium intracellulare antigens; Mycobacterium avium antigens; Treponema antigens; Pertussis antigens; Schistosoma antigens; Filaria antigens; Herpes virus antigens; influenza and parainfluenza virus antigens; measles virus antigens; mumps virus antigens; hepatitis virus antigens; Shigella antigens; Neisseria antigens; rabies antigens, polio virus antigens; Rift Valley Fever virus antigens; dengue virus antigens; measles virus antigens; Human Immunodeficiency Virus (HIV) antigens; respiratory syncytial virus (RSV) antigens; snake venom antigens;

and Vibrio cholera antigens. Enzymes which may be encoded include, but are not limited to, steroid enzymes.

Anti-tumor agents which may be encoded by the second DNA sequence include, but are not limited to, interferon- α , interferon- β , or interferon- γ , and tumor necrosis factor, or TNF. Lymphokines which may be encoded include, but are not limited to, interleukins 1 through 8.

Reporter molecules which may be encoded include, but are not limited to, luciferase, B-galactosidase, B-glucuronidase, and catechol dehydrogenase.

Other peptides or proteins which may be encoded by the second DNA sequence include, but are not limited to, those which encode for stress proteins, which can be administered to evoke an immune response or to induce tolerance in an autoimmune disease (e.g., rheumatoid arthritis).

Selectable markers which may be encoded include, but are not limited to, the kanamycin resistance marker, the neomycin resistance marker, the chloroamphenicol resistance marker, and the hygromycin resistance marker.

The phage DNA portion of the present invention, which includes the first DNA sequence encoding mycobacterium phage integration into a mycobacterium chromosome, and the second DNA sequence encoding at least one protein or polypeptide heterologous to mycobacteria, may be constructed through genetic engineering techniques known to those skilled in the art. In a preferred embodiment, the phage DNA portion may be a plasmid including, in addition to the DNA encoding integration and the DNA encoding a heterologous protein, an origin of replication for any of a wide variety of organisms, which includes, but is not limited to, E.coli, Streptomyces species, Bacillus species, Staphylococcus species, Shigella species, Salmonella species and various species of pneumococci. Most preferably, the plasmid includes an origin of replication for E.coli.

The phage DNA portion also may include a suitable promoter. Suitable promoters include, but are not limited to, mycobacterial promoters such as the BCG HSP60 and HSP70 promoters; mycobactin promoters of M. tuberculosis and BCG, the superoxide dismutase promoter, the α -antigen promoter of M. tuberculosis and BCG, the MBP-70 promoter, the 45 kda antigen promoter of M. tuberculosis and BCG; and the mycobacterial asd promoter; the mycobacterial 14 kda and 12 kda antigen promoters; mycobacteriophage promoters such as the Bxb1 promoter, the L1 and L5 promoters, and the TM4 promoters; E.coli promoters; or any other suitable promoter. The selection of a suitable promoter is deemed to be within the scope of those of ordinary skill in the art from the teachings contained herein.

The promoter sequence may, in one embodiment, be part of an expression cassette which also includes a portion of the gene normally under the control of the promoter. For example, when a mycobacterial HSP60 or HSP70 promoter is employed, the expression cassette may include, in addition to the promoter, a portion of the gene for the HSP60 or HSP70 protein. When the expression cassette and the DNA encoding the heterologous protein or polypeptide are expressed, the protein expressed by the cassette and the DNA encoding the heterologous protein or polypeptide is a fusion protein of a fragment of a mycobacterial protein (eg., the HSP60 or HSP70 protein), and the heterologous protein.

In a preferred embodiment, the transcription initiation site, the ribosomal binding site, and the start codon, which provides for the initiation of the translation of mRNA, are each of mycobacterial origin. The stop codon, which stops translation of mRNA, thereby terminating synthesis of the heterologous protein, and the transcription termination site, may be of mycobacterial origin, or of other bacterial origin, or such stop codon and transcription termination site may be those of the DNA encoding the heterologous protein or polypeptide.

The phage DNA portion may be employed, as hereinabove indicated, for integration into a mycobacterial chromosome, thereby transforming the mycobacteria, and whereby the mycobacteria will express protein(s) or polypeptide(s) heterologous to mycobacteria. Such mycobacteria may be utilized in the production of a vaccine or a therapeutic agent, depending upon the protein(s) or polypeptides expressed by the transformed mycobacteria. To form such a vaccine or therapeutic agent, the transformed mycobacteria are administered in conjunction with a suitable pharmaceutical carrier. As representative examples of suitable carriers there may be mentioned: mineral oil, alum, synthetic polymers, etc. Vehicles for vaccines and therapeutic agents are well known in the art and the selection of a suitable vehicle is deemed to be within the scope of those skilled in the art from the teachings contained herein. The selection of a suitable vehicle is also dependent upon the manner in which the vaccine or therapeutic agent is to be administered. The vaccine or therapeutic agent may be in the form of an injectable dose and may be administered intramuscularly, intravenously, orally, intradermally, or by subcutaneous administration.

Other means for administering the vaccine or therapeutic agent should be apparent to those skilled in the art from the teachings herein; accordingly, the scope of the invention is not to be limited to a particular delivery form.

When the transformed mycobacteria are employed as a vaccine, such a vaccine has important advantages over other presently available vaccines. Mycobacteria have, as hereinabove indicated, adjuvant properties among the best currently known and, therefore, stimulate a recipient's immune system to respond with great effectiveness. This aspect of the vaccine induces cell-mediated immunity and thus is especially useful in providing immunity against pathogens in cases where cell-mediated immunity appears to be critical for resistance. Also, mycobacteria may stimulate long-term memory or immunity. It thus may be possible

to prime long-lasting T cell memory, which stimulates secondary antibody responses neutralizing to the infectious agent or the toxin. Such priming of T cell memory is useful, for example, against tetanus and diphtheria toxins, pertussis, malaria, influenza virus, Herpes virus, rabies, Rift Valley fever virus, dengue virus, measles virus, Human Immunodeficiency Virus (HIV), respiratory syncytial virus, human tumors, and snake venoms. Another advantage in employing mycobacteria transformed with the phage DNA portion of the present invention as a vaccine or a therapeutic agent is that mycobacteria in general have a large genome (i.e., approximately 3×10^6 base pairs in length). Because the genome is large, it is able to accommodate a large amount of DNA from other source(s), and may possibly be employed to make a vaccine and/or therapeutic agent containing DNA sequences encoding more than one antigen and/or therapeutic agent.

Also, because the integrated gene(s) of interest has not been lost following non-selective growth of transformed mycobacteria, the gene(s) of interest will continue to be expressed by the transformed mycobacteria following administration of the mycobacteria to a host. Such mycobacteria, therefore, are effective vehicles for expressing antigens which stimulate an immune response, or for the expression of therapeutic(s) agents such as anti-tumor agents and/or anti-cancer agents.

The invention will now be described with respect to the following examples; however, the scope of the present invention is not to be limited thereby.

Example 1

- A. Identification of the DNA sequences of the attachment sites, attB, attL, and attR, of M. smegmatis.

Using standard technologies, a lambda EMBL3 library was prepared from BamHI digested mc²61 chromosomal DNA (mc²61 is a

strain of M. smegmatis which includes an M. smegmatis chromosome into which has been integrated the genome of mycobacterial phage L5) and digested with Bam HI. Phage L5 contains DNA having restriction sites identical to those of phage L1 (Snapper, et al. 1988), except that L5 is able to replicate at 42°C and phage L1 is incapable of such growth. This library was then probed with a 6.7 kb DNA fragment isolated from the L5 genome that had been previously identified as carrying the attP sequence (Snapper, et al 1988). One of the positive clones was plaque purified, DNA prepared, and a 1.1 kb Sal I fragment (containing the AttL sequence) sub-cloned into sequencing vector pUC119. The DNA sequence of this fragment was determined using a shotgun approach coupled with Sanger sequencing. By isolating and sequencing the attL junction site and comparing this to the DNA sequence of L5 that was available, a region was determined where the two sequences aligned but with a specific discontinuity present. The discontinuity represents one side of a core sequence, which is identical in attP, attB, and attL. The region containing the recombinational crossover point is shown in Figure 1.

The attL DNA (1.1 kb Sal I fragment) was used as a probe to hybridize to a Southern blot of Bam HI digested mc²⁶ DNA, which is a strain of M. smegmatis which includes an M. smegmatis chromosome without any phage integration (Jacobs, et al, 1987, hereinabove cited.). A single band of approximately 6.4 kb was detected corresponding to the attB sequence of M. smegmatis. This same attL probe was used to screen a cosmid library of mc²⁶ (provided by Dr. Bill Jacobs of the Albert Einstein College of Medicine of Yeshiva University), and a number of positive cosmid clones were identified. DNA was prepared from these clones, and a 1.9 kb Sal I fragment (containing the attB site) that hybridizes to the attL probe was subcloned into pUC119 for sequencing and further analysis. The DNA sequence containing the core sequence was determined and is shown in Figure 1. The core

sequence, which is identical in attP, attB and attL, has a length of 43bp.

The mc²61 lambda EMBL3 library was then probed with the 1.9kb SalI fragment containing the attB site. Positive plaques were identified, DNA was prepared, and analyzed by restriction analysis and Southern blots. Lambda clones were identified that contained a 3.2kb Bam HI fragment containing the putative attR site. The 3.2kb Bam HI fragment was purified and cloned into pUC119 for sequencing and further analysis.

B. Determination of attP-integrase region of L5 genome.

Concurrent with the above procedures, a significant portion of the DNA sequence of L5 had been determined and represented in several "contigs" or islands of DNA sequence. Sequences of the 6.7kb Bam HI fragment hereinabove described were determined by (a) analysis of the location of Bam HI sites in the contigs of the DNA of L5, and (b) by determining a short stretch of DNA sequence from around the Bam HI sites of plasmid pJR-1 (Figure 6), which carries the 6.7kb Bam HI fragment of L5.

A segment of DNA sequence was located that represented the 6.7kb Bam HI fragment of phage L5. Studies of other phages have shown that the integrase genes are often located close to the attP site. It was thus determined that the L5 integrase (int) gene should lie either within the 6.7kb Bam HI fragment or in a DNA sequence on either side of it. The DNA sequence in the regions was then analyzed by translating it into all six possible reading frames and searching these amino acid sequences for similarity to the family of integrase related proteins, and through computer-assisted analysis of the DNA sequence. As shown in Figure 2, there are shown two domains of reasonably good conservation among L5 integrase and other integrases, and three amino acid residues that are absolutely conserved in domain 2. (See Yagil, et al., J. Mol. Biol., Vol. 207, pgs. 695-717 (1989), and Poyart-Salmeron, et al., J. EMBO, Vol. 8, pgs. 2425-2433 (1989)). A region was identified, and analysis of the

corresponding DNA sequence showed a reading frame that could encode for a protein of approximately 333 amino acids. These observations identified the putative int gene.

The location of the int gene was not within the 6.7kb Bam HI fragment; however, it was very close to it with one of the Bam HI sites (that defines the 6.7kb Bam HI fragment) less than 100 bp upstream of the start of the gene. Analysis of the Bam HI sites showed that the int gene lay within a 1.9kb Bam HI fragment located adjacent to the 6.7kb Bam HI fragment. This 1.9kb Bam HI fragment was cloned by purification of the fragment from a Bam HI digest of L5 DNA and cloning into pUC 119, to generate pMH1 (Figure 7).

From a combination of the above approaches, a schematic of the organization of the attP-int region of L5 was constructed (Figure 3), and the gene sequence of the attP-int region is given in Figure 4.

C. Construction of pMH5.

The 6.7kb Bam HI fragment of mycobacteriophage L5, which contains the attP site, as hereinabove described, was cloned into the Bam HI site of pUC 119 (Figure 5). This was achieved by purifying the 6.7kb Bam HI fragment from a Bam HI digest of L5 DNA separated by agarose gel electrophoresis and ligating with Bam HI cut pUC 119. DNA was prepared from candidate recombinants and characterized by restriction enzyme analysis and gel electrophoresis. A recombinant was identified that contained the 6.7kb Bam HI fragment of L5 cloned into pUC 119. This plasmid was named pJR-1, as shown in Figure 6.

Analysis of DNA sequence data from a project to sequence L5 showed that a 1.9kb Bam HI fragment adjacent to the 6.7kb Bam HI fragment hereinabove described contained the integrase gene.

A plasmid containing a 1.9kb Bam HI fragment containing the DNA encoding for the integrase cloned into the Bam HI site of pUC 119 was constructed. The 1.9kb fragment was purified from a Bam

HI digest of L5 DNA and cloned into the Bam HI site of pUC 119. Construction of the recombinant was determined by restriction analysis and gel electrophoresis. This plasmid was called pMH1, the construction of which is shown schematically in Figure 7.

pJR-1 was then modified by digestion with EcoRI and SnaBI (both are unique cloning sites), between which is a Bam HI site. The Eco RI-Sna BI fragment, including the Bam HI site was excised, and the plasmid was religated to form plasmid of pMH2, which contains one Bam HI site compared to two Bam HI sites contained in pJR-1. A schematic of the construction of pMH2 is shown in Figure 8.

The 1.9kb Bam HI fragment, which includes the integrase gene, was purified from a Bam HI digest of pMH1 and ligated to Bam HI digested pMH2. Recombinants were identified as above and the orientation of the 1.9kb fragment determined. A plasmid called pMH4 was thus constructed (Figure 9) in which the region from the Sna BI site (upstream of attP) through to the Bam HI site (downstream of the integrase gene) was identical to that in L5.

pMH4 was digested with HindIII (unique site) and was ligated to a 1kb HindIII fragment purified from pKD43 (supplied by Keith Darbyshire of the Nigel Gindley Laboratory) that contains the gene determining resistance to kanamycin. Recombinants were identified and characterized as above. This plasmid is called pMH5. A schematic of the construction of pMH5 is shown in Figure 10.

D. Integration of pMH5 into attB of *M. smegmatis*.

Plasmids pYUB12 (a gift from Dr. Bill Jacobs a schematic of the formation of which is shown in Figure 20), pMD01 (Figure 11), and pMH5 were electroporated, with four different concentrations of plasmid DNA over a 1,000-fold range, into *M. smegmatis* strain mc²155, a strain which is able to support plasmid replication. In Examples 1 and 2, all electroporation procedures of *M. smegmatis*, or of BCG, were carried out as follows:

Cultures of organism were grown in Middlebrook 7H9 media, as described by Snapper, et al. (1988), harvested by centrifugation, washed three times with cold 10% glycerol, and resuspended at approximately a 100 x concentration of cells.

1 μ l of DNA was added to 100 μ l of cells in an ice-cold cuvette and pulsed in a Bio-Rad Gene Pulser, and given a single pulse at 1.25 kv at 25 μ F. 1 ml of broth was added the cells incubated for 1 hr. at 37°C for expression of the antibiotic-resistant marker. Cells were then concentrated and plated out on Middlebrook or tryptic soy media containing 15 μ g/ml kanamycin. Colonies were observed after 3 to 5 days incubation at 37°C.

Each of pYUB12, pMD01, and pMH5 carries kanamycin resistance. Plasmid pYUB12 carries an origin of DNA replication, while pMD01 lacks a mycobacterial origin of replication. Plasmid pMH5 does not carry a mycobacterial origin of replication, but carries a 2kb region of phage L5 which contains the attP site and the integrase gene (Figure 4). The number of transformants were linear with DNA concentration. Plasmid pYUB12 gives a large number of transformants (2×10^5 per μ g DNA) in mc²155, while pMH5 gives 6×10^4 transformants per μ g DNA, and pMD01 gives no transformants.

The above experiment was then repeated by electroporating the plasmids pYUB12, pMD01, and pMH5 into M. smegmatis strain mc²6, which does not support plasmid replication. No transformants in mc²6 were obtained from pYUB12 or pMD01, while pMH5 gave approximately 10^4 kanamycin resistant transformants in mc²6 per μ g of DNA, thus indicating integration of pMH5 into the mc²6 chromosome.

DNA from six independent pMH5 transformants (four in mc²155 and two in mc²6) was prepared. These DNA's (along with DNA from both mc²155 itself, and mc²155 carrying the plasmid pYUB12) were digested with a restriction enzyme, and analyzed by Southern blot and hybridization with the M. smegmatis 1.9kb attB probe

hereinabove described. As shown in Figure 12, all six transformants have integrated into the attB site, resulting in the production of two new DNA fragments with different mobilities. If pMH5 did not integrate into the attB site, it would be expected that a single band, corresponding to the attB site in the mc²155 control, would be obtained.

E. Construction of pMH9.2 and pMH9.4

pUC119 was digested with HindIII, and a 1kb HindIII fragment, containing a kanamycin resistance gene, purified from pKD43, was ligated to the HindIII digested pUC119 to form pMH8 (Figure 13.). A 2kb SalI fragment of pMH5 (bp 3226-5310), which carries the attP and integrase gene from SalI digested pMH5, was purified and inserted in both orientations relative to the vector backbone of SalI digested pMH8 to form plasmids pMH9.2 and pMH9.4 (Figures 14 and 15).

F. Stability of plasmids in M. smegmatis

M. smegmatis strain mc²155 cells carrying, as a result of electroporation, plasmid pYUB12, pMH9.2 or pMH9.4, or strain mc²6 cells carrying plasmid pMH5, as a result of electroporation as hereinabove described, were grown to saturation in broth with kanamycin. Cultures were then diluted 1:100 into broth without kanamycin and grown to saturation. Two further cycles of dilution and growth were done, corresponding to about 20 generations of bacterial growth. Cultures were plated out to single colonies on non-selective plates, and approximately 100 of these colonies were patch plated onto both non-selective and selective plates. The % of colonies that were sensitive to kanamycin, thus corresponding to the percentage of cells which lost the plasmid, is given below in Table I.

Table I

	<u>% loss</u>
pYUB12 (mc ² 155)	35
pMH5 (mc ² 6)	17
pMH9.2 (mc ² 155)	3

pMH9.4 (mc²155)

0

Example 2

The 1.9 kb Sal I fragment, which includes the M. smegmatis attB site as hereinabove described was cloned into pUC119, and the plasmid generated was named pMH-12. (Figure 16).

Gel purified Sal I 1.9kb M. smegmatis fragment containing attB (isolated from pMH-12) was used to probe a Southern transfer of Bam HI digested mycobacterial DNA's, including BCG substrain Pasteur, shown in Figure 17. This demonstrated that there is one Bam HI fragment of BCG that strongly hybridizes to the M. smegmatis attB probe and three hybridize weakly. The strongest hybridizing band is the fastest moving band (approximately 1.9 kb).

The same probe as above was used to probe a BCG cosmid library (provided by Dr. Bill Jacobs) and positive clones were identified. DNA was prepared from several positive clones and analyzed by restriction analysis and Southern blotting. The 1.9 kb Bam HI fragment (corresponding to the strongly hybridizing band in the Southern blot) was identified, gel purified from the cosmid DNA and cloned into pUC119. The resulting plasmid was named pMH-15. (Figure 18).

Plasmids pMH-5 and pMH9.4 were electroporated into BCG Pasteur. It was observed that pMH9.4 transforms BCG with high efficiency (approximately 10^4 transformants/ μ g DNA), while pMH-5 transforms BCG at low efficiency (1-10 transformants/ μ g DNA). DNA was prepared from BCG transformants and analyzed by Bam HI restriction and Southern blot analysis, probing with gel purified 1.9kb Bam HI BCG attB fragment from pMH-15. These data are shown in Figure 19 and show that integration of both pMH 5 and pMH 9.4 is specific to the BCG attB site (ie. the strongly cross-hybridizing fragment in BCG). This is illustrated by the loss of the 1.9kb Bam HI fragment from the transformants and the appearance of two new bands representing attL and attR junction fragments. Figure 19 shows just one of the pMH 5/BCG

transformants, although all of the four that were analyzed show that one of the bands (the largest) is smaller than expected (and different in each of the transformants), indicating that the transformation efficiency of pMH 5 is low in BCG. In contrast, the four pMH 9.4 transformants are identical to each other (Figure 19) and give attR and attL junction fragments of the predicted sizes.

Example 3

A. Construction of plasmids including mycobacterial promoter expression cassette.

1. Construction of pYUB125

Plasmid pAL5000, a plasmid which contains an origin of replication of M. fortuitum, and described in Labidi, et al., FEMS Microbiol. Lett., Vol. 30, pgs. 221-225 (1985) and in Gene, Vol. 71, pgs. 315-321 (1988), is subjected to a partial Sau 3A digest, and 5kb fragments are gel purified. A 5kb fragment is then ligated to Bam HI digested pIJ666 (an. E. coli vector containing an E. coli origin of replication and also carries neomycin-kanamycin resistance, as described in Kieser, et al., Gene, Vol. 65, pgs. 83-91 (1988) to form plasmid pYUB12. A schematic of the formation of plasmid pYUB12 is shown in Figure 20. pYUB12 and pIJ666 were then transformed into M. smegmatis and BCG. Neomycin-resistant transformants that were only obtained by pYUB12 transformation confirmed that pAL5000 conferred autonomous replication to pIJ666 in M. smegmatis and BCG.

Shotgun mutagenesis by Snapper, et al (1988, hereinabove cited) indicated that no more than half of the pAL5000 plasmid was necessary to support plasmid replication in BCG. This segment presumably carried open reading frames ORF1 and ORF2, identified by Rauzier, et al., Gene, Vol. 71, pgs. 315-321 (1988), and also presumably carried a mycobacterial origin of replication. pYUB12 is then digested with HpaI and EcoRV, a 2586 bp carrying this region or segment of pAL5000 is removed and

ligated to PvuII digested pYUB8. Plasmid pYUB8 (a pBR322 derivative) includes an E. coli replicon and a kan^R (aph) gene. Ligation of the 2586 bp pYUB12 fragment to PvuII digested pYUB8 results in the formation of pYUB53, as depicted in Figure 21. Transformation of pYUB53 confirmed that the EcoRV-HpaI fragment, designated M.rep, was capable of supporting autonomous replication in BCG.

Plasmid pYUB53 was then digested with AatI, EcoRV, and PstI in order to remove the following restriction sites:

AatI 5707
EcoRI 5783
BamHI 5791
Sali 5797
PstI 5803
PstI 7252
Sali 7258
BamHI 7264
EcoRI 7273
ClaI 7298
HindIII 7304; and
EcoRV 7460

Fragment ends are then flushed with T4 DNA polymerase and religated to form plasmid pYUB125, construction of which is shown in Figure 22.

2. Elimination of superfluous vector DNA from pYUB125

792 bases of the tet gene, which had been inactivated by prior manipulations, was eliminated by a complete NarI digest, gel purification of the 6407 bp fragment, and ligation/recirculation, transformation of E. coli strain HB101, and selection of Kan^R transformants. The construction of the resulting plasmid, pMV101, is schematically indicated in Figure 23, and the DNA sequence of pMV101, which includes markings of regions which will be deleted and of mutations, as hereinafter described, is shown in Figure 24.

3. Elimination of undesirable restriction sites in aph (kan^R) gene.

To facilitate future manipulations, the HindIII and ClaI restriction sites in the aph gene were mutagenized simultaneously by polymerase chain reaction PCR mutagenesis according to the procedure described in Gene, Vol. 77 pgs. 57-59 (1989). The bases changed in the aph gene were at the third position of codons (wobble bases) within each restriction site and the base substitutions made were designed not to change the amino acid sequence of the encoded protein.

Separate PCR reactions of plasmid pMV101 with primers ClaMut-Kan + HindRMut-Kan and HindFMat-Kan + Bam-Kan were performed at 94°C (1 min.), 50°C (1 min.), and 72°C (1 min.) for 25 cycles. The PCR primers had the following base sequences:

ClaMut-Kan

CTT GTA TGG GAA GCC CC

HindRMut-Kan

GTG AGA ATG GCA AAA GAT TAT GCA TTT CTT TCC AG

HindFMat-Kan

GTC TGG AAA GAA ATG CAT AAT CTT TTG CCA TTC TCA CCG G

Bam-Kan

CGT AGA GGA TCC ACA GGA CG

The resulting PCR products were gel purified and mixed and a single PCR reaction without primers was performed at 94°C (1 min.), 72°C (1 min.) for 10 cycles. Primers ClaMut-Kan and Bam-Kan were added and PCR was resumed at 94°C (1 min.), 50°C (1 min.), and 72°C (2 min.) for 20 cycles. The resulting PCR product (Kan. mut) was digested with BamHI and gel purified. Plasmid pMV101 was digested with ClaI and cohesive ends were filled in by Klenow + dCTP + dGTP. Klenow was heat inactivated and the digest was further digested with BamHI. The 5232 base pair fragment was gel purified and mixed with fragment Kan.mut and ligated. The ligation was transformed into E.coli strain HB101 and Kan^R colonies were screened for plasmids resistant to

ClaI and HindIII digestion. Such plasmids were designated as pMV110, which is depicted in Figure 23.

4. Elimination of sequences not necessary for plasmid replication in mycobacteria.

Plasmid pMV110 was resected in separate constructions to yield plasmids pMV111 and pMV112. In one construction, pMV110 was digested with NarI and Ball, the ends were filled in, and a 5296 base pair fragment was ligated and recircularized to form pMV111. In another construct, pMV110 was digested with NdeI and SphI, the ends were filled in, and a 5763 base pair fragment was ligated and recircularized to form pMV112. Schematics of the constructions of pMV111 and pMV112 are shown in Figure 25. These constructions further eliminated superfluous E. coli vector sequences derived from pAL5000 not necessary for mycobacterial replication. Cloning was performed in E. coli. Plasmids pMV111 and pMV112 were tested for the ability to replicate in M. smegmatis. Because both plasmids replicated in M. smegmatis the deletions of each plasmid were combined to construct pMV113.

To construct pMV113 (Figure 25), pMV111 was digested with BamHI and EcoRI, and a 1071 bp fragment was isolated. pMV112 was digested with BamHI and EcoRI, and a 3570 bp fragment was isolated, and then ligated to the 1071 bp fragment obtained from pMV111 to form pMV113. These constructions thus defined the region of pAL5000 necessary for autonomous replication in mycobacteria as no larger than 1910 base pairs.

5. Mutagenesis of restriction sites in mycobacterial replicon.

To facilitate further manipulations of the mycobacterial replicon, PCR mutagenesis was performed as above to eliminate the Sal I, EcoRI, and BglII sites located in the open reading frame known as ORF1 of pAL5000. PCR mutagenesis was performed at wobble bases within each restriction site and the base substitutions were designed not to change the amino acid sequence of the putative encoded ORF1 protein. The restriction sites were eliminated one at a time for testing in mycobacteria. It was

possible to eliminate the SalI and EcoRI without altering replication in M. smegmatis. In one construction, PCR mutagenesis was performed at EcoRI1071 of pMV113 with primers Eco Mut - M.rep and Bam-M.rep. to form pMV117, which lacks the EcoRI1071 site. Primer Eco Mut - M.rep has the following sequence:

TCC GTG CAA CGA CGT GTG TCC CGG A;

and Bam-M.rep has the following sequence:

CAC CCG TCC TGT GGA TCC TCT AC.

In another construction, PCR mutagenesis was performed at the SalI 1389 site with primer Sal Mut - M.rep and Bam-M.rep to form pMV119, which lacks the SalI 1389 site. Primer Sal Mut - M.rep has the following sequence:

TGG CGA CCG CAG TTA CTC AGG CCT.

pMV117 was then digested with ApaLI and BglII, and a 3360 bp fragment was isolated. pMV119 was digested with ApaLI and BglII, and a 1281 bp fragment was isolated and ligated to the 3360 bp fragment isolated from pMV117 to form pMV123. A schematic of the constructions of plasmids pMV117, pMV119, and pMV123 is shown in Figure 26. Elimination of the BglII site, however, either by PCR mutagenesis or Klenow fill in, eliminated plasmid replication in mycobacteria, thus suggesting that the BglII site is in proximity to, or within a sequence necessary for mycobacteria plasmid replication.

6. Construction of pMV200 series vectors.

To facilitate manipulations of all the components necessary for plasmid replication in E. coli and mycobacteria, (E. rep. and M. rep.) and selection of recombinants (Kan^R), cassettes of each component were constructed for simplified assembly in future vectors and to include a multiple cloning site (MCS) containing unique restriction sites and transcription and translation terminators. The cassettes were constructed to allow directional cloning and assembly into a plasmid where all transcription is unidirectional.

Kan^R Cassette

A DNA cassette containing the aph (Kan^R) gene was constructed by PCR with primers Kan5' and Kan3'. An SpeI site was added to the 5' end of PCR primer Kan3', resulting in the formation of a PCR primer having the following sequence:

CTC GAC TAG TGA GGT CTG CCT CGT GAA G.

Bam HI + NheI sites were added to the 5' end of PCR primer Kan5', resulting in the formation of a PCR primer having the following sequence:

CAG AGG ATC CTT AGC TAG CCA CCT GAC GTC GGG G.

PCR was performed at bases 3375 and 4585 of pMV123, and BamHI and NheI sites were added at base 3159, and an SpeI site was added at base 4585. Digestion with BamHI and SpeI, followed by purification resulted in a 1228/2443 Kan^R cassette bounded by BamHI and SpeI cohesive ends with the direction of transcription for the aph gene proceeding from BamHI to Spe I.

E. rep. cassette

A DNA cassette containing the ColEI replicon of pUC19 was constructed by PCR with primers E.rep/Spe and E.rep/Mlu. An SpeI site was added to the 5' end of PCR primer E.rep/Spe, and an MluI site was added to the 5' end of PCR primer E.rep./Mlu. The resulting primers had the following base sequences:

E.rep./Spe

CCA CTA GTT CCA CTG AGC GTC AGA CCC

E.rep./Mlu

GAC AAC GCG TTG CGC TCG GTC GTT CGG CTG.

PCR was performed at bases 713 and 1500 of pUC19, and an MluI site was added to base 713, and a SpeI site was added to base 1500. Digestion with MluI and SpeI, followed by purification resulted in an E.rep. cassette bounded by SpeI and MluI cohesive ends with the direction of transcription for RNA I and RNA II replication primers proceeding from SpeI to MluI.

M.rep. cassette

A DNA cassette containing sequences necessary for plasmid replication in mycobacteria was constructed by PCR of pMV123 with primers M.rep/Mlu and M.rep/Bam. An MluI site was added to the 5' end of PCR primer M.rep/Mlu. A BamHI site was added to the 5' end of PCR primer M.rep/Bam. The resulting PCR primers had the following base sequences:

M.rep./Mlu

CCA TAC GCG TGA GCC CAC CAG CTC CG

M.rep./Bam

CAC CCG TCC TGT GGA TCC TCT AC

PCR was performed at bases 134 and 2082 of pMV123. An MluI site was added to base 2082. Digestion with BamHI and MluI, followed by gel purification resulted in a 1935 base pair DNA cassette bounded by MluI and BamHI cohesive ends with the direction of transcription for the pAL5000 ORF1 and ORF2 genes proceeding from MluI to Bam HI.

The Kan^R, E.rep, and M.rep PCR cassettes were then mixed in equimolar concentrations and ligated, and then transformed in E.coli strain HB101 for selection of Kan^R transformants. Colonies were screened for the presence of plasmids carrying all three cassettes after digestion with BamHI + MluI + SpeI and designated pMV200. An additional restriction site, NcoI, was eliminated from the M.rep cassette by digestion of pMV200 with NcoI, fill in with Klenow, and ligation and recircularization, resulting in the formation of pMV201. A schematic of the formation of pMV200 from pMV123 and pUC19, and of pMV201 from pMV200, is shown in Figure 27. Plasmids pMV200 and pMV201 were transformed into M. smegmatis and BCG. Both plasmids yielded Kan^R transformations, thus indicating their ability to replicate in mycobacteria.

A synthetic multiple cloning sequence (MCS) (Figure 28) was then designed and synthesized to facilitate versatile molecular cloning and manipulations for foreign gene expressions in mycobacteria, and for integration into the mycobacterial

chromosome. The synthetic MCS, shown in Figure 28, contains 16 restriction sites unique to pMV201 and includes a region carrying translation stop codons in each of three reading frames, and a transcription terminator derived from *E. coli* 5S ribosomal RNA (T1).

To insert the MCS cassette, pMV201 was digested with *NarI* and *NheI*, and the resulting fragment was gel purified. The MCS was digested with *HinPI* and *NheI* and, the resulting fragment was gel purified. The two fragments were then ligated to yield pMV204. A schematic of the construction of pMV204 is shown in Figure 29.

Plasmid pMV204 was then further manipulated to facilitate removal of the M.rep cassette in further constructions. pMV204 was digested with *MluI*, and an *MluI* - *Not I* linker was inserted into the *MluI* site between the M.rep and the E.rep to generate pMV206. A schematic of the construction of pMV206 from pMV204 is shown in Figure 30, and the DNA sequence of pMV206 is given in Figure 31.

7. Construction of expression cassette based on BCG HSP60.

Among the most abundant proteins in mycobacteria is the HSP60 heat shock protein (also known as the 65 kda antigen). Because abundance of the HSP60 protein in mycobacteria indicates strong HSP60 gene expression, the sequence controlling HSP60 expression was chosen to control expression of heterologous genes encoding antigens or other proteins in BCG.

The published sequence of the BCG HSP60 gene (Thole, et al, Infect. and Immun., Vol. 55, pgs. 1466-1475 (June 1987)), and surrounding sequence permitted the construction of a cassette carrying expression control sequences (i.e., promoter and translation initiation sequences) by PCR. The BCG HSP61 cassette (Figure 32) contains 375 bases 5' to the BCG HSP60 start codon, and 15 bases (5 codons) 3' to the start codon. PCR oligonucleotide primers were then synthesized. Primer Xba-HSP60, of the following sequence:

CAG ATC TAG ACG GTG ACC ACA ACG CGC C
was synthesized for the 5' end of the cassette, and primer
Bam-HSP61, of the following sequence:

CTA GGG ATC CGC AAT TGT CTT GGC CAT TG
was synthesized for the 3' end of the cassette. The primers were
used to amplify the cassette by PCR from BCG substrain Pasteur
chromosomal DNA. The addition of the Bam HI site at the 3' end
of the cassette adds one codon (Asp) to the first six codons of
the HSP60 gene.

Each of pMV206 and the PCR cassette HSP61 was digested with
Xba I and Bam HI. The PCR cassette was then inserted between the
Xba I and Bam HI sites of pMV206, and then ligated to form
pMV261, which is shown in Figure 33.

The E. coli lac Z gene was used as a reporter, or marker
gene to assay the ability of the HSP61 cassette to express
heterologous genes in BCG. A BamHI^r restriction fragment carrying
the lac Z gene was cloned into the Bam HI site of Bam HI digested
pMV261, resulting in the formation of pMV261/LZ. A schematic of
the construction of pMV261/LZ is shown in Figure 34. The
formation of pMV261/LZ results in a fusion between the HSP60 and
lac Z genes at the sixth codon of the HSP60 gene and the sixth
codon of the lac Z gene. pMV261/LZ was then transformed into E.
coli. Blue E. coli colonies were selected on x-gal plates for
the presence of pMV261/LZ, thus indicating that the HSP60
promoter and translation initiation sequences were also active in
E. coli.

pMV261/LZ was then transformed into BCG and plated on Dubos
Oleic Agar plates containing x-gal. All BCG colonies resulting
from this transformation exhibited blue color, thus indicating
that the lac Z gene product (B-galactosidase) was expressed in
BCG. SDS polyacrylamide gel electrophoresis was performed on
lysates of the pMV261/LZ BCG recombinant, revealing that
B-galactosidase protein was expressed to levels in excess of 10%
of total BCG protein (as determined by staining with Coomassie

brilliant blue). These data indicated that BCG HSP61 expression cassette was functional in expression vector pMV261, and that substantial expression of a heterologous gene could be achieved using HSP60 - controlled expression in BCG.

Plasmid pMV261/LZ was then shown to replicate autonomously, and express the E. coli B-galactosidase, or lacZ gene, driven by the BCG promoter HSP60, in M. smegmatis and BCG.

B. Transfer of mycobacterial phage L5 integration sequences to BCG expression vector.

Plasmid pMH9.4, which includes the mycobacterial phage L5 attP site and the L5 integrase gene, was digested to completion with either KpnI + PvuII or XbaI + PvuII, and a restriction fragment of 1862 or 1847 base pairs, respectively, each of which contain the attP site and the integrase gene, were purified by agarose gel electrophoresis. Plasmid pMV261/LZ was digested with XbaI + DraI to generate either a 7569 bp or 7574 bp vector fragment. The 7569 bp fragment was ligated to the 1862 bp fragment derived from pMH9.4 to form pMV460F/LZ. The 7574 bp fragment was ligated to the 1847 bp fragment derived from pMH9.4 to form pMV460R/LZ. Plasmids pMV460 F/LZ and pMV460R/LZ each include a mycobacterial replicon, the L5 attP site, and the L5 integrase gene. A schematic of the formation of plasmids pMV460 F/LZ and pMV460R/LZ is shown in Figure 35. To generate derivatives without the mycobacterial plasmid replicon, plasmids pMV460F/LZ and pMV460R/LZ were digested with NotI and recircularized by ligation to generate pMV360F/LZ and pMV360R/LZ. A schematic of the construction of pMV360F/LZ and pMV360R/LZ is shown in Figure 36.

Plasmids pMH9.4, pMV261/LZ, pMV460F/LZ, pMV460R/LZ, pMV360F/LZ, and pMV360R/LZ were then transformed into M. smegmatis and BCG to test their ability to replicate autonomously or integrate into the M. smegmatis or BCG chromosome. Transformation with pMH9.4, pMV261/LZ, pMV360F/LZ, and pMV360R/LZ yielded kanamycin resistant transformants of M. smegmatis and

BCG. Transformants of pMV261LZ, pMV360F/LZ, and pMV360R/LZ were shown to express E. coli B-galactosidase by SDS-polyacrylamide gel electrophoresis and X-gal assay as hereinabove described for pMV261/LZ. Plasmids pMV461F/LZ and pMV461R/LZ failed to yield kanamycin resistant transformants, thus indicating that chromosomal integration of a plasmid carrying sequences mediating autonomous replication is lethal to mycobacteria.

Example 4

A. Construction of expression cassettes based on BCG HSP70.

A partial sequence of the 5' region of the BCG HSP70 gene (which encodes for the BCG HSP70 heat shock protein, also known as the 70 kda antigen) obtained by Dr. Rick Young (MIT) permitted the construction of cassettes carrying expression control sequences (i.e., promoters and translation initiation sequences) by PCR, according to the procedures hereinabove cited. The BCG-HSP71 cassette (Figure 32) contains 150 bases 5' to the BCG-HSP70 start codon and 15 bases (5 codons) 3' to the start codon. Primer Xba-HSP70 was synthesized for the 5' end of the cassette, and primer Bam-HSP71 was synthesized for the 3' end of the cassette. The primers had the following base sequences:

Xba-HSP70

GGC CTC TAG ACC CGC ACG ACC AGC GTT AGC

Bam-HSP71

GCT AGG ATC CCC GAC CGC ACG AGC CAT GGT

The primers were used to amplify the cassette from BCG substrain Pasteur chromosomal DNA. The addition of the Bam HI site at the 3' end of the cassette adds 1 codon (Asp) to the 3' end of the HSP71 expression cassette.

Each of pMV206 and the PCR cassette HSP71 was digested with XbaI and BamHI. The PCR cassette was then inserted between the XbaI and BamHI sites of PMV 206, and then ligated to form pMV271, which is shown in Figure 33.

B. Cloning of HIV-1gag.

A BamHI-ClaI PCR cassette of HIV-1 gag was cloned between the Bam HI and Cla I sites of pMV261 and pMV271 to obtain pMV261/gag and pMV271/gag. Expression of the gag antigens in BCG was verified by the appearance of immunoreactive protein bands in Western blot analysis of BCG pMV271/gag recombinant lysates. BCG transformants, however, were never obtained with pMV261/gag, thus indicating that gag as expressed from pMV26/gag was lethal.

C. Integration of HSP60-gag expression cassette into BCG.

In order to test whether integration of an HSP-60-gag expression cassette into BCG would result in non-lethal expression of gag in BCG, it was decided that the HSP60-gag expression cassette be cloned into a plasmid (pMV307) which includes the mycobacteriophage L5 attP and integrase sequences, the construction of which is explained hereinbelow.

1. Construction of pMV307.

Plasmid pMV206 was digested with NotI to remove the mycobacterial replicon. The resulting 2209 bp fragment, which includes the aph (Kan^R) gene, the E.coli replicon and the multiple cloning site, was ligated and recircularized to form pMV205, the construction of which is schematically depicted in Figure 30.

PCR with primers XbaI-Att/Int and NheI-Att/Int was then performed on a Sal I fragment from pMH9.4, which contains the attP site and the L5 integrase gene. The resulting cassette was then digested with XbaI and NheI, and a 1789 bp fragment was gel purified. pMV205 was then digested with NheI, and the resulting fragment was ligated to the 1989 bp fragment obtained from pMH9.4 to form pMV307. A schematic of the construction of pMV307 is shown in Figure 37.

2. Construction and transformation of pMV361/gag.

The XbaI-ClaI HSP-antigen cassette, which includes the HSP60 promoter and HIV-1gag sequences, was cloned between the NotI and ClaI sites of pMV307 to form plasmid pMV361/gag. pMV361/gag was

then transformed into BCG and shown to express HIV-1 gag protein by Western blot analysis with HIV-1 infected human sera.

Example 5

A series of antigen gene fragments, or cassettes, were constructed by PCR, with the exception of the gene fragment containing the gene for human tumor antigen p97, as indicated in Table 2, and cloned into various restriction sites of pMV261 and pMV271 to form new constructs of the pMV261 and pMV271 series. The antigen genes, antigen gene fragments, cloning sites used in pMV261 and pMV271 and the names of the resulting constructs, are given below in Table 2.

The following constructs:

pMV261/P97
pMV271/P97
pMV261/CS
pMV271/CS
pMV261/SM97
pMV271/SM97
pMV271/HIV-1-gag
pMV261/HIV-1gp120
pMV271/HIV-1gp120
pMV261/HIV-1-gp41
pMV271/HIV-1-gp41
pMV261/HIV2gag
pMV271/HIV2gag
pMV261/HIV2-gp120
pMV271/HIV2-gp120
pMV261/HIV2-gp41; and
pMV271/HIV2-gp41.

were transformed into BCG, and the presence of the corresponding antigens in BCG was verified by the appearance of immunoreactive protein bands in Western blot analysis of BCG recombinant lysates.

Example 6

Antigen gene expression cassettes, which include a promoter sequence and a heterologous gene sequence, were excised from the pMV261 and pMV271 derivatives with NotI and a second restriction enzyme site (Pvu II, Eco RI, Sal I, Cla I or Hind III) and cloned into the integrating plasmid pMV307 between the NotI site and a second enzyme site (Pvu II, Eco RI, Sal I, Cla I or Hind III) to form the pMV 361/XXX and pMV371/XXX series of plasmids (e.g., pMV361/HIV-1gp120). The backbones of these series of plasmids (pMV361 and pMV371) are shown in Figure 38.

The following plasmids:

pMV361/P97

pMV371/P97
pMV361/CS
pMV371/CS
pMV361/SM97
pMV371/SM97
pMV361/HIV-1gag
pMV371/HIV-1gag
pMV361/HIV-1gp120
pMV371/HIV-1gp120
pMV361/HIV-1gp41
pMV371/HIV-1gp41
pMV361/HIV2gag
pMV371/HIV2gag
pMV361/HIV2-gp120; and
pMV361/HIV2-gp41.

were transformed into BCG and shown to express the corresponding antigens by Western blot analysis with the appropriate antigen-specific human sera.

It is to be understood, however, that the scope of the present invention is not to be limited to the specific embodiments described above. The invention may be practiced other than as particularly described and still be within the scope of the accompanying claims.

WHAT IS CLAIMED IS:

1. A DNA for integrating DNA into a mycobacterium chromosome, comprising:
a first DNA sequence which is a phage DNA portion encoding bacteriophage integration into a mycobacterium chromosome; and
a second DNA sequence encoding a protein or polypeptide which is heterologous to the mycobacterium in which the DNA is to be integrated.
2. The DNA of Claim 1 wherein said phage DNA portion encodes mycobacteriophage integration into a mycobacterium chromosome.
3. The DNA of Claim 1 wherein said first DNA sequence includes DNA encoding integrase.
4. The DNA of Claim 3 wherein said first DNA sequence includes DNA encoding an AttP site.
5. The DNA of Claim 4 wherein said first DNA sequence encodes integration into BCG.
6. The DNA of Claim 5 wherein the DNA is a plasmid including an origin of replication for E. coli.
7. The DNA of Claim 1 wherein the first DNA sequence is selected from the group consisting of Figure 4 and analogues and derivatives thereof which encode for integration into mycobacteria.
8. Mycobacteria transformed with the DNA of Claim 1.
9. BCG having foreign DNA integrated into the chromosome.
10. A vaccine comprising: the transformed mycobacteria of Claim 8; and an acceptable pharmaceutical carrier.
11. A process for providing a protein, comprising:
expressing the protein in the mycobacteria of Claim 8.

AAAACACCCCTCTGACCAGCCGAGCGGGCGACGGGAATCGAACCCGCGTAGCTAGTTTGGGAAGATGGGTGTCTGCCGACCACA attP

AAAACACCCCTCTGACCAGCCGAGCGGGCGACGGGAATCGAACCCGCGTAGCTAGTTTGGGAAGCTAGGGCTCTACCATTGAGC attL

CGCACCGTGGCGGTCCCTACCGAGCGGGCGACGGGAATCGAACCCGCGTAGCTAGTTTGGGAAGCTAGGGCTCTACCATTGAGC attB

Figure 1

Domain 1

INT (λ)
 INT (HK22)
 INT (φ 80)
 INT (P2)
 INT (P4)
 INT (P22)
 INT (186)
 INT (HP1)
 INT (L54a)
 Cre (P1)
 D Prot. (F)
 Flm B
 Flm E
 Tn2603 ORF3
 Tn554 TopA
 Tn554 TopB
 Tn4430 Top1
 Rci
 Tn1545 ORF2
 Flp
 R1AMELAVVTGQGVGDLCCEMKWSDIVDG
 R1ANDLAVVTGQGVGDLCCEMKWSDINDN
 VFLVKEIMLTGTCRTAEIRLSERSWFRLD
 KKIAILCLSTGARWGEAARLKAENI11IN
 MIAVKLSILTFVRSSELRFAWDEFDFD
 KSVVEFALSTGLRNSNIINLEMOQIDMQ
 ETVVRICLATGARWSEAESELRKSQLAKY
 GLIVRICLATGARWSEAESELTQSQVMPY
 AGAVEQALTCMRIGELLALQVKDVLK
 TAGVEKALSIGVTKLVERWISVSGVADD
 KMILATLWNTGARINEALALTRGDFSLA
 YCLTLICFINGFRASEICRLRISDIDLK
 YCLILLAYRHGHRISELLDLHYQDIDLN
 RLFAQLLYGTGMRISEGLQLRVKDIDFD
 KLIIMHYEGGLRIGEVLSIRLEDIVTM
 ATHTHIVQECGMRISELCTLRKKGCLIFD
 YAIATLLAYTGVRISEALSIRKNDENLQ
 YVIFILALETMRQOEILAIRWEHIDLIR
 YDEILILLKTGLRISFEGGLTLPLDIDFE

CONSENSUS --lv-l-l-TGmR-SEl--Lr--di---
 L5 R1AAYILANTSLRFGELIELRRKDIVDD

Domain 2

HELRSLSA-RLYEKO-ISDKFAQHLLGHKS-DTHASQYR-
 HELRSLSA-RLYRNQ-IGDKFAQRLLGHKS-DSMAARYRD
 HDHRTIATNLSELG-CPPHVIEKLLGHQM-VGVMAHYN-
 HALLRSFATHFING-GSIIILQRIILGHTR-IEQTMVYAH
 HGFRTMARGALGESGLWSDDAIERQSLHSERNVRAAYIH
 HDLRITWASHLVQAG-VPISVLQEMGGWES-IEHVRRYAH
 HVLRHTFASHFEMNG-GNILLVQLQVGLHTD-INKMTHRYAH
 HVLRHTFASHFEMNG-GNILLVKEILGHST-IEMTMRYAH
 HTLRHTHISLLAEMN-ISLKAIMKRVGHRDEKTIKVVYTH
 HSARVGAARDMARAG-VSIPFIMOAGGWTN-VNIVMNYIR
 HTFRHSYAMHMLYAG-IPLKVLQSLMGHKS-ISSTEVYTK
 HMLRHSCGFALANMG-IDTRLIQDYLGHRN-IRHTVRYTA
 HMLRHACGYELAERG-ADTRLIQDYLGHRN-IRHTVRYTA
 HTLRHSFATALLRSG-YDINTVQDLLGHSD-VSTTHIYTH
 HMLRHTHATQLIREG-WDVAFVQKRLGHANVQTTLTIVH
 HAFRHTVGTIRMING-HPQHIVQKFLGHES-PEHTSRYAH
 HQLRHFFCTNAIEKG-FSIEHVAHQAGHSN-IHTTLLYT-
 HDLRHEAISRFEELGSLAVVHEIAAISGHSR-MNMLKRYTH
 HSLRHTFCTNYANAG-MNPKALQYINGHAN-IAHTLNYIA
 HIGRHLMTSFLSMKGLTELTVVGVNWSDKRASAVATTYTH

* *
 H-LRht-At-L---G---l---lQ-lLgh---l---T---Y-H
 HDLRVAGATFAAQAG-ATTKELMARLGHST-PRMANKYQM

Figure 2

L5 Bam HI sites





Figure 3




Figure 4

1301 GACCGTCCGGTCCAAGCGTCTGTGACGGTTCCGCCCTACGTCCGGGAGATGATCCGAGCGCACATGAAGGACCGTACGAAGATGAACAAAGGCCCGGAG
Int CTGGCAGGCCAGCTTCGCAGGACACTGCCAAGGCCGAGTCCAGCGCCCTCTAGTAGGCTCGCGTGTACTTCTTGGCATGCTTCTACTTGTTCGGGGCTC 1400
T V R S K R P V T V P P H V A E M I R A H M K D R T K M N K G P E -

1401 GCATTCTGGTGACCAGGACGCGAGGGCAACCGGCTGTGGAAGTCCGCGTTCACCAAGTCGCTGAAGCGTGGCTACGCCAAGATCGGTGCGCGGAACTCC
Int CGTAAGGACCACTGGTGTGCGTCCCGTTGGCGGACAGCTTCAGGCCCAAGTGGTTCAGCGACTTCGCACCGATGCGGTTCTAGCCAGCGCGCTTGAGG 1500
A F L V T T T Q G N R L S K S A F T K S L K R G Y A K I G R P E L R -

1501 GCATCCAGCACTCCGCGCTGTGCGGCTACGTTCCGCCCTCAGGCAGGTGCGGACGACCAAGGAGGTGATGGCGCGTCTCGGTACACGACTCTTAGGAT
Int CGTAGGTCTGGAGGCGCGACAGCGCGATGCCAAGCGGCGAGTCCGTCACGCTCTCGTTCTCGACTACCGCGGAGAGCCAGTGTGCTGAGGATCCTA 1600
I H D L R A V G A T F A A Q A G A T T K E L M A R L G H T T P R M -

1601 GCGGATGAAGTACCAGATGGCGTCTGAGGCGCGGACGAGGCTATCGCTGAGGCGATGTCCAAGCTGGCCCAAGACCTCTGAAACGCAAAAAGCGCGCGT
Int CCGCTACTTCTATGGTCTACCGCAGACTCCGGGCGGTGCTCGGATAGCGACTCCGCTACAGGTTCCAGCGGTTCTGAGGACTTTCCGTTTTTCCGGGGGA 1700
A M K Y Q M A S E A R D E A I A E A M S K L A K T S -
Int stop

1701 CCCAAGGACACTGAGTCTTAAGAGGGGGTTCCTTCTCAGTACGCGAAGAACCACGCTGGCGCGGAGCGCGCAGCACCGCGCTCTGTGCGGAGACCTG
GGGTTCTGTGACTCAGGATTCTCTCCCCCAAGAACAGTCAATGCGCTTCTTGGTGGGACCGCGGCTCGCGGTCTGGCGGCGAGACACGCTCTGGAC 1800

PvuII
I
1801 GGCACGAGCCCCCGCGCCCGCAGGAGCATTGCGGTTCCCGCCAGCTGAGTTCTGTTGTGCGCGCGCTATGTAGAGCTGGTCTGTAGGTCCGATCTCCA
CCGTGGTCCGGGCGGCGCGGTCTCTGTAACGGCAAGGGCGGTGCACTCAAGACAACACGCGCGGATACATCTCGACCAGCAACATCCAGGCTAGAGGT 1900

1901 GCGGACTTTCGGCGGACGCTGAGGATGTGATCAGAGCCCTCGGGACCGCGGTTGGGGTCAAACCTGACCATCCGACAGCGGACGCGGTGGTGTTC
CCGCTGAAAGGCGCGCTGCGACTCTTACAGCTAGTGTCTCGGAGGCCCTGGCGGCCAAGCCAGTTTGGACTGGTAGGCTGTCCGCTGCGGCACCAAAAG 2000

SalI
I
2001 CTCCAGGGCCTCCGGCCTTGCTGAGAATACAGAGCCAGGTCCCGCTCGGCTCCAGCTCCGACGAGCCCGGTGATCGTCTTGGTGCAC 2089
GAGGTCCCGAGGCGGAACGGACTCTTATGTCCTGGTTCGAGGCGGACGCGGAGGTTCGAGGCTGCTCGGGCCACTAGCAGAACCAAGCTG






Figure 5



Shaded portion = LS DNA

Figure 6



Shaded portion = L5⁻ DNA

Figure 7





Figure 8



Shaded portion = L5 DNA

Figure 9





Figure 10



Shaded portion = Kan^R cassette

Figure 11





FIGURE 12



Shaded portion = Kan^R cassette

Figure 13





Figure 14

*Figure 15*




Figure 16




Figure 17




Figure 18





Figure 19

Figure 20






Figure 21




Figure 22




Figure 23




Figure 24

Deleted in pAVIII, 113-2005

[illegible]

[illegible]




Figure 23




Figure 26




Figure 27

Synthetic Multiple Cloning Site (MCS) + Strand

GAA GGC GCG GCC GCG GTA CCA GAT CTT TAA ATC TAG ATA TCC ATG GAT
CCA GCT GCA GAA TTC GAA GCT TAT CGA TGT CGA CGT AGT TAA CTA GCG
TAC GAT CGA CTG CCA GGC ATC AAA TAA AAC GAA AGG CTC AGT CGA AAG
ACT GGG CCT TTC GTT TTA TCT GTT GTT TGT CCG GCC ATC ATG GCC GCG
GTG ATC AGC TAG TAC G

Figure 28




Figure 29




Figure 30

pMV206

N
h Begin Kan Cassette
•
•
•
101 GCTAGCCAAACAAAGCGAGCTGTGTCTCAAAATGTCTGATTTACATTGACAAAGATAAAAAATATATCATCATCAACAAATAAACTGTCTGCTTACATAA
120 CGATCGGTGTCTCTGCTGCAACACAGAGTTTACAGACTACAATGTAACGTGTCTATTTTATATAGTAGTACTTTGTTATTTTACAGACCAATGTATT
140
160 Kan start codon
181 ACACTAATACAAGGGGTGTTATAGCCATATTCACGGGAACGTCTTCTGTCAGGGCCGATTTAAATTCACATGGATGCTGATTTATATGGGTATAA
200 TGTCTATTATGTTCCCAACAACTACTGGTATAAGTGGCGTTTCCAGAACGAGCTCCGGCGCTAAATTAAGGTTGTACCTACCACTAAATATACCCATATT
220
N
C
D
•
•
•
201 ATGGGCTGGGATAATGTCTGGGAATCAGGTGCGACAACTATGCTTTATGTTGGGAAGGGCATGCGCCACAGTTGTTCTGAAACATGGCAAGGTAGC
220 TACCGGAGCGCTATTACAGCGCGTTAGTCCACGCTGTTAGATAGCGAACAATACCGTTGGGGTACGGGTTGTAACAAAGACTTTGTACCGTTTCTGATCG
240
261 GTTGGCAATGATGTTACAGATGAGATGGTCAGACTAACTGGGTGACGGAACTTATGCTTTTCCGACCATCAAGCATTTTATCGGTACTGCTGATGATG
280 CAACGGTTACTACAAATGTCTACTCTACCACTGTGATTTGACCGACTGCGTTAAATACGGAGAAGGCTGGTAGTCTGTAATAATAGGCACTAGGACTACTAC
300
321 CATGTTACTGACCACTGGGATCGCGGGGAAACAGCAATTCAGGTATTAGAGAATATCGTGAATCAGGTGAAATATTGTTGATGCGGTGGCAGTGT
340 GTACCAATCAGTGGTGACGCTAGCGGGCGTTTTGTGTTAAGGTGCATAATCTTTTATAGGACTAAGTGCACCTTTATACAACTACGGACCGTCACAA
360
381 GGTGCGCGCGTTGCATTGCAATGCTGTGTTGTAATGTCTTTTAAACGGGATCGGCTATTTGCTGCTGCTCAGGGCGAATCAGGAATGAATACGGTTG
400 GGACCGCGCGCAAGGTAAAGGTAAAGGACAAACATTAAACAGGAAATGTGCTGAGCGCATAAAGCAGAGCGAGTCCGGCTTAGTGTCTACTTATTCGCAAC
420
441 GTTGATGCGAGTGATTTTGATGACGAGCTAATGCTGCGCTGTGAAACAGTGTGGAAAGAAATGCATATCTTTTCCCATTTCTACCGGATTTAGTGG
460 CAACCTAGCTCTACTAAACTACTGCTGCACTTACCGGACAACTTTTTCAGACTTTTCTACGTATTAGAAACGGTTAAGAGTGGCTAAGTCAGC
480
501 TCACTCATGGTGATTTCTCACTTGATAACCTTATTTTACGAGCGGAAATTAATAGGTGTGATTGATGTTTGGACGAGTGGGAATCGCAGACGGATACCA
520 AGTGAGTACCACTAAAGAGTGAACCTATTGGAAATAAACTGCTCGCGCTTAATATTCACATAACTACAACTGCTCAGCGTTAGCGTCTGGCTATGTT
540
561 GGATGTTGCCATGCTATGGAATGCGTGGTGAGTTTCTGCTTCACTACAGAAACGGCTTTTCAAAAATATGGTATTGATTAATGCTGATATGAATAA
580 GGTAGAAGGTTAGGATACCTGACGGAGCGCTCAAAAGAGGAAGTAAATGCTTTGCGGAAAAGTTTTATACCATAACTATTAGGACTATACTTATTT
600
621 TTTGAGTTTCACTTTGATGCTGATGAGTTTTCTGATCAGAAATTGGTTGTAACACTGGCAGAGCATACGCTGACTTGACGGGAGCGGGCGCT
640 AACCTCAAGTAAACTACGAGCTACTCAAAAGATTAGTCTTAACCAATTAAACCAATGTGACCGTCTGTAATGGAGTGAAGTGGCGTGGCGCGCA
660
681 TTTTGAAATAATCGAAGTTTTGCTGAGTTGAAGGATCAGATCAGCATCTTCCGACAAACGAGACCGTTCCGTTGGCAAGCAAAAGTTCAAAATCACC
700 AACAACTTATTAGCTTGAAACGACTCAAGTTCTGAGTCTAGTGGTAGAAGGCGTGTGCGTCTGGCAAGGCACCGTTTCTGTTTCAAGTTTATGTTG
720
741 AACTGTTCCACTTACAAACAAAGCTCTCATCAACGGTGGCTCCCTCACTTTCTGCTTGGATGATGGGGCGATTGAGGCTGGTATGAGTCAGCAACACTT
760 TTGACCAAGGTGGATGTTGTTTGGAGAGTAGTTGGCACCGAGGGAGTGAAGACCGACTACTACCGCGCTAAGTCCGGACCATAGTCACTGTTGTGGAA
780
801
821
841
861
881
901
921
941
961
981
1001
1021
1041
1061
1081
1101
1121
1141
1161
1181
1201
1221
1241
1261
1281
1301
1321
1341
1361
1381
1401
1421
1441
1461
1481
1501
1521
1541
1561
1581
1601
1621
1641
1661
1681
1701
1721
1741
1761
1781
1801
1821
1841
1861
1881
1901
1921
1941
1961
1981
2001
2021
2041
2061
2081
2101
2121
2141
2161
2181
2201
2221
2241
2261
2281
2301
2321
2341
2361
2381
2401
2421
2441
2461
2481
2501
2521
2541
2561
2581
2601
2621
2641
2661
2681
2701
2721
2741
2761
2781
2801
2821
2841
2861
2881
2901
2921
2941
2961
2981
3001
3021
3041
3061
3081
3101
3121
3141
3161
3181
3201
3221
3241
3261
3281
3301
3321
3341
3361
3381
3401
3421
3441
3461
3481
3501
3521
3541
3561
3581
3601
3621
3641
3661
3681
3701
3721
3741
3761
3781
3801
3821
3841
3861
3881
3901
3921
3941
3961
3981
4001
4021
4041
4061
4081
4101
4121
4141
4161
4181
4201
4221
4241
4261
4281
4301
4321
4341
4361
4381
4401
4421
4441
4461
4481
4501
4521
4541
4561
4581
4601
4621
4641
4661
4681
4701
4721
4741
4761
4781
4801
4821
4841
4861
4881
4901
4921
4941
4961
4981
5001
5021
5041
5061
5081
5101
5121
5141
5161
5181
5201
5221
5241
5261
5281
5301
5321
5341
5361
5381
5401
5421
5441
5461
5481
5501
5521
5541
5561
5581
5601
5621
5641
5661
5681
5701
5721
5741
5761
5781
5801
5821
5841
5861
5881
5901
5921
5941
5961
5981
6001
6021
6041
6061
6081
6101
6121
6141
6161
6181
6201
6221
6241
6261
6281
6301
6321
6341
6361
6381
6401
6421
6441
6461
6481
6501
6521
6541
6561
6581
6601
6621
6641
6661
6681
6701
6721
6741
6761
6781
6801
6821
6841
6861
6881
6901
6921
6941
6961
6981
7001
7021
7041
7061
7081
7101
7121
7141
7161
7181
7201
7221
7241
7261
7281
7301
7321
7341
7361
7381
7401
7421
7441
7461
7481
7501
7521
7541
7561
7581
7601
7621
7641
7661
7681
7701
7721
7741
7761
7781
7801
7821
7841
7861
7881
7901
7921
7941
7961
7981
8001
8021
8041
8061
8081
8101
8121
8141
8161
8181
8201
8221
8241
8261
8281
8301
8321
8341
8361
8381
8401
8421
8441
8461
8481
8501
8521
8541
8561
8581
8601
8621
8641
8661
8681
8701
8721
8741
8761
8781
8801
8821
8841
8861
8881
8901
8921
8941
8961
8981
9001
9021
9041
9061
9081
9101
9121
9141
9161
9181
9201
9221
9241
9261
9281
9301
9321
9341
9361
9381
9401
9421
9441
9461
9481
9501
9521
9541
9561
9581
9601
9621
9641
9661
9681
9701
9721
9741
9761
9781
9801
9821
9841
9861
9881
9901
9921
9941
9961
9981
10001
10021
10041
10061
10081
10101
10121
10141
10161
10181
10201
10221
10241
10261
10281
10301
10321
10341
10361
10381
10401
10421
10441
10461
10481
10501
10521
10541
10561
10581
10601
10621
10641
10661
10681
10701
10721
10741
10761
10781
10801
10821
10841
10861
10881
10901
10921
10941
10961
10981
11001
11021
11041
11061
11081
11101
11121
11141
11161
11181
11201
11221
11241
11261
11281
11301
11321
11341
11361
11381
11401
11421
11441
11461
11481
11501
11521
11541
11561
11581
11601
11621
11641
11661
11681
11701
11721
11741
11761
11781
11801
11821
11841
11861
11881
11901
11921
11941
11961
11981
12001
12021
12041
12061
12081
12101
12121
12141
12161
12181
12201
12221
12241
12261
12281
12301
12321
12341
12361
12381
12401
12421
12441
12461
12481
12501
12521
12541
12561
12581
12601
12621
12641
12661
12681
12701
12721
12741
12761
12781
12801
12821
12841
12861
12881
12901
12921
12941
12961
12981
13001
13021
13041
13061
13081
13101
13121
13141
13161
13181
13201
13221
13241
13261
13281
13301
13321
13341
13361
13381
13401
13421
13441
13461
13481
13501
13521
13541
13561
13581
13601
13621
13641
13661
13681
13701
13721
13741
13761
13781
13801
13821
13841
13861
13881
13901
13921
13941
13961
13981
14001
14021
14041
14061
14081
14101
14121
14141
14161
14181
14201
14221
14241
14261
14281
14301
14321
14341
14361
14381
14401
14421
14441
14461
14481
14501
14521
14541
14561
14581
14601
14621
14641
14661
14681
14701
14721
14741
14761
14781
14801
14821
14841
14861
14881
14901
14921
14941
14961
14981
15001
15021
15041
15061
15081
15101
15121
15141
15161
15181
15201
15221
15241
15261
15281
15301
15321
15341
15361
15381
15401
15421
15441
15461
15481
15501
15521
15541
15561
15581
15601
15621
15641
15661
15681
15701
15721
15741
15761
15781
15801
15821
15841
15861
15881
15901
15921
15941
15961
15981
16001
16021
16041
16061
16081
16101
16121
16141
16161
16181
16201
16221
16241
16261
16281
16301
16321
16341
16361
16381
16401
16421
16441
16461
16481
16501
16521
16541
16561
16581
16601
16621
16641
16661
16681
16701
16721
16741
16761
16781
16801
16821
16841
16861
16881
16901
16921
16941
16961
16981
17001
17021
17041
17061
17081
17101
17121
17141
17161
17181
17201
17221
17241
17261
17281
17301
17321
17341
17361
17381
17401
17421
17441
17461
17481
17501
17521
17541
17561
17581
17601
17621
17641
17661
17681
17701
17721
17741
17761
17781
17801
17821
17841
17861
17881
17901
17921
17941
17961
17981
18001
18021
18041
18061
18081
18101
18121
18141
18161
18181
18201
18221
18241
18261
18281
18301
18321
18341
18361
18381
18401
18421
18441
18461
18481
18501
18521
18541
18561
18581
18601
18621
18641
18661
18681
18701
18721
18741
18761
18781
18801
18821
18841
18861
18881
18901
18921
18941
18961
18981
19001
19021
19041
19061
19081
19101
19121
19141
19161
19181
19201
19221
19241
19261
19281
19301
19321
19341
19361
19381
19401
19421
19441
19461
19481
19501
19521
19541
19561
19581
19601
19621
19641
19661
19681
19701
19721
19741
19761
19781
19801
19821
19841
19861
19881
19901
19921
19941
19961
19981
20001
20021
20041
20061
20081
20101
20121
20141
20161
20181
20201
20221
20241
20261
20281
20301
20321
20341
20361
20381
20401
20421
20441
20461
20481
20501
20521
20541
20561
20581
20601
20621
20641
20661
20681
20701
20721
20741
20761
20781
20801
20821
20841
20861
20881
20901
20921
20941
20961
20981
21001
21021
21041
21061
21081
21101
21121
21141
21161
21181
21201
21221
21241
21261
21281
21301
21321
21341
21361
21381
21401
21421
21441
21461
21481
21501
21521
21541
21561
21581
21601
21621
21641
21661
21681
21701
21721
21741
21761
21781
21801
21821
21841
21861
21881
21901
21921
21941
21961
21981
22001
22021
22041
22061
22081
22101
22121
22141
22161
22181
22201
22221
22241
22261
22281
22301
22321
22341
22361
22381
22401
22421
22441
22461
22481
22501
22521
22541
22561
22581
22601
22621
22641
22661
22681
22701
22721
22741
22761
22781
22801
22821
22841
22861
22881
22901
22921
22941
22961
22981
23001
23021
23041
23061
23081
23101
23121
23141
23161
23181
23201
23221
23241
23261
23281
23301
23321
23341
23361
23381
23401
23421
23441
23461
23481
23501
23521
23541
23561
23581
23601
23621
23641
23661
23681
23701
23721
23741
23761
23781
23801
23821
23841
23861
23881
23901
23921
23941
23961
23981
24001
24021
24041
24061
24081
24101
24121
24141
24161
24181
24201
24221
24241
24261
24281
24301
24321
24341
24361
24381
24401
24421
24441
24461
24481
24501
24521
24541
24561
24581
24601
24621
24641
24661
24681
24701
24721
24741
24761
24781
24801
24821
24841
24861
24881
24901
24921
24941
24961
24981
25001
25021
25041
25061
25081
25101
25121
25141
25161
25181
25201
25221
25241
25261
25281
25301
25321
25341
25361
25381
25401
25421
25441
25461
25481
25501
25521
25541
25561
25581
25601
25621
25641
25661
25681
25701
25721
25741
25761
25781
25801
25821
25841
25861
25881
25901
25921
25941
25961
25981
26001
26021
26041
26061
26081
26101
26121
26141
26161
26181
26201
26221
26241
26261
26281
26301
26321
26341
26361
26381
26401
26421
26441
26461
26481
26501
26521
26541
26561
26581
26601
26621
26641
26661
26681
26701
26721
26741
26761
26781
26801
26821
26841
26861
26881
26901
26921
26941
26961
26981
27001
27021
27041
27061
27081
27101
27121
27141
27161
27181
27201
27221
27241
27261
27281
27301
27321
27341
27361
27381
27401
27421
27441
27461
27481
27501
27521
27541
27561
27581
27601
27621
27641
27661
27681
27701
27721
27741
27761
27781
27801
27821
27841
27861
27881
27901
27921
27941
27961
27981
28001
28021
28041
28061
28081
28101
28121
28141
28161
28181
28201
28221
28241
28261
28281
28301
28321
28341
28361
28381
28401
28421
28441
28461
28481
28501
28521
28541
28561
28581
28601
28621
28641
28661
28681
28701
28721
28741
28761
28781
28801
28821
28841
28861
28881
28901
28921
28941
28961
28981
29001
29021
29041
29061
29081
29101
29121
29141
29161
29181
29201
29221
29241
29261
29281
29301
29321
29341
29361
29381
29401
29421
29441
29461
29481
29501
29521
29541
29561
29581
29601
29621
29641
29661
29681
29701
29721
29741
29761
29781
29801
29821
29841
29861
29881
29901
29921
29941
29961
29981
30001
30021
30041
30061
30081
30101
30121
30141
30161
30181
30201
30221
30241
30261
30281
30301
30321
30341
30361
30381
30401
30421
30441
30461
30481
30501
30521
30541
30561
30581
30601
30621
30641
30661
30681
30701
30721
30741
30761
30781
30801
30821
30841
30861
30881
30901
30921
30941
30961
30981
31001
31021
31041
31061
31081
31101
31121
31141
31161
31181
31201
31221
31241
31261
31281
31301
31321
31341
31361
31381
31401
31421
31441
31461
31481
31501
31521
31541
31561
31581
31601
31621
31641
31661
31681
31701
31721
31741
31761
31781
31801
31821
31841
31861
31881
31901
31921
31941
31961
31981
32001
32021
32041
32061
32081
32101
32121
32141
32161
32181
32201
32221
32241
32261
32281
32301
32321
32341
32361
32381
32401
32421
32441
32461
32481
32501
32521
32541
32561
32581
32601
32621
32641
32661
32681
32701
32721
32741
32761
32781
328

[illegible]

HSP61 Cassette

1 TCTAGAGGTTGACCACAACGACGGGGCCCGCTTTGATCGGGGACGTCTCGGGCCGACCATTTACGGGCTCTGTGTCTGTTGGCGGTCATGGCGGCAACATAC 100
CGATCGCCACTGGTGTCTGCTGCGGGGGGGAACCTAGCCCGCTGCAGACGCGGGCTGGTAAATGCCCAGAACACAGCAACCGCCAGTACCGGGCTTGTATG

101 TCACCGGATCGGAGGGCCGAGGACAAAGTCCAAAGAGGGGATGACCCGCTCGGGGCTTCTTCACCTGGGCATAGGGGAGTGTAAAGAATAACGTTGG 200
AGTGGGGCTAGCGTCCCGGGCTCGTGTTCAGCTTGGTCCCGGTACTGGGGCAGCGCCGGAAGAAGCTGAGCGGTATCCGCTCAGGATTCTTATTGCAACC

201 CACTCCGACCGGTGAGTCTTAGTTCGGGACGGTGCAGGCCAGGGCCGCTGCTCCAGCGAGTGGCAGCGAGGACAACCTGAGCCGCTCGCTCGGGGCACTG 300
GTGAGCGGCTCGCCAGTCAAGCATCCAGCCCTGCCACTCCGGTCCGGGCAGCAGCGTCCGCTCAGCGTCCGCTCTGTGAACTCGGCAGGCAGCGCGCGTAC

301 CCGCCCGCCAGCGTAAGTAGCGGGGTTCGGGTCCACCGGGTGACCCCGGTTTCATCCCGGATCGGGAGGAATCACTTCGCAATGGCCAAAGACAATTCGGGAGGG 400
GGCGGGCGGTCGCATTCATCGCCCAACGGCAGTGGGCCACTGGGGGGCAAAGTAGGGGCTAGGGCTCTTAGTGAAAGCGTTACCGGTTCTGTAAAGCGGTAGG
M A K T : A D P

HSP71 Cassette


1 TCTAGACCCGACGACCAAGCGTTAGCATGCTCAGTAAGTTGAGTGCATCAGGCTCAGCTCTGAATTGACAGCACACCGCCGTCGAGGCAAGCTTGACGGG 100
AGATCTGGGCGTGTCTGGTCCGAATCGTAGGATCAITCAACTCAGCTACTCCGAGTCCGAGACTTAACGTCTGTGTGGCGGCAGCTCCGTTCCGAATCGCC

101 GGTGCACCTCATCATAGTGCAGGAAGAAGCTCTACATATTGAGGAGGATTACCATGGCTCTGTCGGTCCGGGATCC 177
CCACGTGAGTAGTATCAGCTGCTTTCTTCGAGATGTATAAGTCTCTCTAAGTGGTACCGAGCACGCCAGCCCTAGG
M A R A V G D P




Figure 32

Construction of HSP60 Cassette
PCR of BCG Genomic DNA
HSP60 Primers
Xba-HSP60 + BamHI-HSP61 - HSP261

HSP70 Primers
Xba HSP70 + BamHI-HSP71 - HSP271



PCF110



Digest w/ BamHI
Ligate w/ BamHI LacZ cassette
Transform *E. coli*
Select blue colonies on X-gal Plates

Digest w/ BamHI
Ligate w/ BamHI LacZ cassette
Transform *E. coli*
Select blue colonies on X-gal Plates





Figure 34







Figure 35



Digest with NotI
Gel Purify 7523 bp fragment
Ligate/Recircularize



Digest with NotI
Gel Purify 7513 bp fragment
Ligate/Recircularize




Figure 36




Figure 37




Figure 38

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/04833

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C12N 15/00, 1/21, 15/11; A61K 39/00 U.S.C1: 536/27; 435/69.1, 252.3; 424/92		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	536/27; 435/172.3, 252.3, 69.1; 424/92	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
Databases: Dialog (Files 5, 155, 350, 351, 399), US PTO Automated Patent System (File US Pat., 1975-1991) search terms: mycobacter ? bacteriophage, integrat ?		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
<u>X</u> Y	WO, A, 90/00594 (Bloom et al) 25 January 1990, see pages 37-39, 64-70 and Figs. 6 7.	1,2,8-11 3-7
<u>X</u> Y	WO, A, 88/06626 (Bloom et al) 07 September 1988, see entire document.	1, 2, 8-11 3-7
<u>X</u> Y	Proceedings of the National Academy of Sciences, volume 85, issued September 1988, Snapper et al., "Lysogeny and transformation in mycobacteria: Stable expression of foreign genes", pages 6987-6991, see the entire document.	1, 2, 8-11 3-7
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
15 October 1991		07 NOV 1991
International Searching Authority		Signature of Authorized Officer
ISA/US		 Nancy Treptow

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
X Y	Reviews of Infectious Diseases volume 11, Supp. 2, issued March-April 1989, Jacobs, Jr. et al., "Myco bacteriophage Vector systems", pages 5404-5410, see entire document.	1, 2, 8-11 3-7
Y	Molecular and General Genetics, volume 195, issued May 1984, Pierson III et al., "Cloning of the integration and attachment regions of bacteriophage P4", pages 44-51, see the entire document.	7
Y	Molecular and General Genetics, volume 192, issued April 1983, Ljungquist et al., "Properties and Products of the cloned <u>int</u> gene of bacteriophage P2," pages 87-94, see the entire document.	7
Y	Journal of Bacteriology, volume 170, No. 12, issued December 1988, Li et al., "Site-specific Integration and expression of a developmental promoter in <u>Myxococcus Xanthus</u> ," pages 5552-5556, see entire document.	7
Y	Journal of Bacteriology, volume 171, No. 3, issued March 1989, Astumian et al., "Site-specific recombination between cloned <u>attP</u> and <u>attB</u> sites from the <u>Haemophilus influenzae</u> bacteriophage HP 1 propagated in recombination-deficient <u>Escherichia coli</u> ," pages 1747-1750, see the entire document.	7